Key points are not available for this paper at this time.
Design
Editorial
No takes yet. Share an insight, caveat, or question.
This editorial discusses the definitions, utility, and pitfalls of using biomarkers and surrogate endpoints in clinical trials, emphasizing the need for a thorough understanding of disease pathophysiology.
Jeffrey K Aronson (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: